Pharvaris N.V. Files 6-K for Jan 5 Press Release

TL;DR

**Pharvaris just dropped a 6-K, likely for a press release, so watch for new info.**

AI Summary

Pharvaris N.V. filed a 6-K on January 8, 2024, to announce a press release issued on January 5, 2024. This filing indicates that the company is providing updated information to the market, likely related to its corporate activities or drug development, as it operates in the pharmaceutical preparations industry. For investors, this matters because press releases often contain material information that can influence stock performance, such as clinical trial updates, regulatory milestones, or financial news, which could impact the value of their shares.

Why It Matters

This filing signals that Pharvaris N.V. has new, potentially market-moving information, which could affect its stock price and investor sentiment.

Risk Assessment

Risk Level: low — This filing itself is administrative and low-risk, merely announcing a press release, but the content of the press release could be high-risk.

Analyst Insight

A smart investor would immediately seek out the attached press release (Exhibit 99.1) to understand the specific information Pharvaris N.V. is disclosing, as its content will determine the actual impact on the company and its stock.

Key Players & Entities

• Pharvaris N.V. (company) — the registrant filing the 6-K
• January 5, 2024 (date) — date the press release was issued
• January 8, 2024 (date) — date the 6-K was filed

Forward-Looking Statements

• The press release (Exhibit 99.1) will contain an update on Pharvaris N.V.'s clinical trials or drug development pipeline. (Pharvaris N.V.) — medium confidence, target: Q1 2024
• The content of the press release will lead to a noticeable movement in Pharvaris N.V.'s stock price. (Pharvaris N.V. stock) — medium confidence, target: January 8, 2024

FAQ

From the Filing

0000950170-24-002680.txt : 20240108 0000950170-24-002680.hdr.sgml : 20240108 20240108070042 ACCESSION NUMBER: 0000950170-24-002680 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 62 CONFORMED PERIOD OF REPORT: 20240108 FILED AS OF DATE: 20240108 DATE AS OF CHANGE: 20240108 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Pharvaris N.V. CENTRAL INDEX KEY: 0001830487 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: P7 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40010 FILM NUMBER: 24518270 BUSINESS ADDRESS: STREET 1: J.H. OORTWEG 21 STREET 2: 2333 CH LEIDEN CITY: LEIDEN STATE: P7 ZIP: 00000 BUSINESS PHONE: 31 (0)71 203 6410 MAIL ADDRESS: STREET 1: J.H. OORTWEG 21 STREET 2: 2333 CH LEIDEN CITY: LEIDEN STATE: P7 ZIP: 00000 FORMER COMPANY: FORMER CONFORMED NAME: Pharvaris, B.V. DATE OF NAME CHANGE: 20201029 6-K 1 corporate_presentation_j.htm 6-K 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934   For the month of January 2024 Commission File Number: 001-40010 Pharvaris N.V. (Translation of registrant’s name into English) Emmy Noetherweg 2   2333 BK Leiden   The Netherlands (Address of principal executive office)   Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐   Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐   Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.   Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐   Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.   PHARVARIS N.V.   On January 5, 2024, Pharvaris N.V. (the “Company”) issued a press release. The press release is attached as Exhibit 99.1 hereto and is incorporated by reference herein. On January 8, 2024, the Company made available an investor presentation on its website. A copy of the investor presentation is attached hereto as Exhibit 99.2. Exhibit 99.1 to this Report on Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form F-3 (Registration Number 333-263198 and 333-273757) and Form S-8 (Registration Number 333-252897). Exhibit 99.2 to this Report on Form 6-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended or the Exchange Act.             SIGNATURES   Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its